TREPROSTINIL | N214324 | UNITED THERAPEUTICS CORP
| Trial # | Patent | Type | Petitioner | Status | Filed | Decision |
|---|---|---|---|---|---|---|
| IPR2020-00769 | 9593066 | IPR | Liquidia Technologies, Inc. | Institution Denied | 2020-03-30 | — |
| IPR2020-00770 | 9604901Delisted | IPR | Liquidia Technolgies, Inc. | Final Written Decision | 2020-03-30 | 2024-08-20 |
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| M.D.N.C. | 2025-05-09 | Active | — | |
| M.D.N.C. | 2025-04-21 | Active | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Lassman Law + Policy FDA-2021-P-0714 · 5 docket documents Scott M. Lassman filed this citizen petition on behalf of a client requesting that the FDA refuse to approve the New Drug Application for Tyvaso DPI (treprostinil dry powder inhalation), a formulation containing FDKP excipient intended for patients with pulmonary arterial hypertension and pulmonary | Other | 2021-07-13 | Denied | Lassman Law + Policy |
Source: Regulations.gov. FDA citizen petitions matched by application number.